1/8/2024 0 Comments Psequel download![]() Results: Fourteen studies were included, of which eight were prospective and half focused in inpatients. Data extraction and critical appraisal were performed independently using a predefined form. Methods: In order to assess the incidence and characteristics of ADR in pediatric patients with oncohematogical diseases and the methodology used in the studies, a systematic review was carried out using both free search and a combination of MeSH terms. However, there is little evidence on pharmacovigilance studies evaluating drug safety in this specific population. Due to the disease severity and chemotherapy safety profile, oncologic patients are at higher risk of ADR. Introduction: Adverse drug reactions (ADR) are an important cause of morbidity and mortality in pediatric patients. Improving the safety and quality of the care processes of children with acute lymphoblastic leukemia is possible, and this should contribute to the mitigation and prevention of adverse events associated morbidity and mortality during the remission induction phase. Of the adverse events, 10.5% were considered preventable and 53.6% could be ameliorable in severity. The presence of adverse events caused 80.2% of hospital readmissions. Infectious processes were the most common severe or higher adverse event (30.5%). ![]() Most adverse events were severe or higher (52.6%). patient-days was estimated, involving 81.2% of patients during induction. One-hundred and eighty-one pediatric patients pediatric patients with acute lymphoblastic leukemia were studied. Adverse events incidence rates were estimated by type, severity, and preventability. Agreement between reviewers was evaluated. Initially, information on patients and adverse events was collected subsequently, two pediatric oncologist reviewers independently classified adverse events, severity and preventability. This study analyzed a cohort based on medical records of between 20. This study aimed to describe the incidence, types, severity, and preventability of adverse events occurring in pediatric patients with acute lymphoblastic leukemia during the induction phase in a tertiary care pediatric hospital in Mexico. Their description allows knowing the safety and quality of the care processes in countries with limited resources. Healthcare-associated adverse events represent a heavy burden of symptoms for pediatric oncology patients. In this narrative review, we examine the pros and cons of several drug dosing methods used when dealing with children who are affected also by obesity, focusing on specific aspects of some of the drugs most frequently prescribed in real-world practice by general pediatricians and pediatric subspecialists. Taking into account the peculiar differences between children with overweight/obesity and those who are normal weight, the drug dosage in the case of obesity, cannot be empirically determined solely by the per kg criterion. Moreover, there is a need for a therapeutic approach, as much as possible tailored considering relevant interacting aspects, such as modification in metabolomic profile, drug pharmacokinetics and pharmacodynamics. However, this method does not consider the pharmacological impact that a specific drug can have under a two-fold point of view, that is, across various age and size groups as well. In general, in pediatric practice, there is a tendency to adapt drug doses to a child’s total body weight. Uncertainties may arise concerning drug dosing when children with obesity need pharmacologic therapies. Childhood obesity and its associated comorbidities are highly prevalent diseases that may add to any other possible health problem commonly affecting the pediatric age.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |